Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of bFGF (basic Fibroblast Growth Factor) to preparation of medicament for treating human ischemic stroke

A brain stroke, human technology, applied in the field of medicine, can solve problems such as blood theft, toxic side effects, uncertain curative effect, etc.

Inactive Publication Date: 2012-10-31
WENZHOU MEDICAL UNIV
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The common characteristics of the above-mentioned therapeutic drugs are: strong pertinence, clear link of action, but single curative effect, difficult to overcome various pathological effects of nerve cell damage caused by ischemic stroke, and have different degrees of toxic and side effects
For example, it is difficult for thrombolytic drugs to enter the damaged brain tissue through the blood-brain barrier to play a role, so the curative effect is uncertain, and there are side effects of causing reperfusion injury and bleeding; vasodilation drugs can dilate blood vessels in normal parts, causing blood flow in lesion areas Normal brain tissue, resulting in the so-called "stealing blood" phenomenon

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bFGF (basic Fibroblast Growth Factor) to preparation of medicament for treating human ischemic stroke
  • Application of bFGF (basic Fibroblast Growth Factor) to preparation of medicament for treating human ischemic stroke
  • Application of bFGF (basic Fibroblast Growth Factor) to preparation of medicament for treating human ischemic stroke

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] 1. Animal experiments:

[0014] Take healthy male B6 mice, weighing 22-25g, SPF grade. The mice were provided by the Experimental Center of Wenzhou Medical College, and the mice were divided into three groups, namely, the normal control group, the model group, and the bFGF treatment group. The mice in the treatment group were intranasally administered bFGF 20 μg / mouse for 1 hour and then underwent bilateral carotid artery ligation cerebral ischemia model (BCCA). After 24 hours and 72 hours of ischemia, spontaneous behavioral analysis, HE staining, and immunohistochemistry were performed. And Western blot analysis. And compare with the model group to get the result.

[0015] 2. Nasal injection in mice:

[0016] Three groups of mice were respectively anesthetized with chloral hydrate of 4% concentration, with 0.01ml / g dose of intraperitoneal anesthesia, then fixed their backs on the wooden board, inserted the thin catheter into the trachea from the mouth of the mouse, ...

Embodiment 2

[0028] 1. PC12 cell H2O2 oxidative damage experiment:

[0029] PC12 cells (rat adrenal medullary pheochromocytoma nerve cell strain) were cultured in DMEM solution containing 10% calf serum, seeded in 96-well plates, and incubated at 37°C and 95% O 2 and 5% CO 2 cultured until the cells confluent into the monolayer. Experiment 1 was divided into 5 groups, namely normal group, H 2 o 2 Concentration of 40, 80, 120, 160μM for 12h. Another experiment was divided into 5 groups, in 120μM H 2 o 2 Under the condition, 0, 20, 40, 80, 160ng / ml bFGF were added sequentially for 12h.

[0030] 2. MTT method to determine the number of living cells:

[0031] The full name of MTT is 3-(4,5-dimethylthiazole-2)-2,5-xylene tetrazolium bromide, and the trade name is thiazole blue. Add the above-mentioned groups of cells to MTT with a total concentration of 0.5mg / ml to react for 4 hours, absorb the supernatant (be careful not to absorb the formazan crystals), add 150M DMSO to each well, and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicine, in particular to an application of a bFGF (basic Fibroblast Growth Factor) to preparation of a medicament for treating human ischemic stroke. During the application of the bFGF (basic Fibroblast Growth Factor) to preparation of the medicament for treating human ischemic stroke, the medicament can be in the forms of a powder injection, a water aqua, a lipoplast and the like. The bFGF can be used of treating ischemic stroke; and a small dosage of bFGF can be used for inhibiting endoplasmic reticulum stress, reducing neuronal apoptosis caused by endoplasmic reticulum, and has a treatment effect on ischemic stroke.

Description

Technical field: [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of basic fibroblast growth factor (bFGF) in the preparation of medicine for treating ischemic cerebral apoplexy. Background technique: [0002] Cerebral stroke, also known as stroke or cerebrovascular accident, is a group of diseases with cerebral ischemia or hemorrhagic injury symptoms as the main clinical manifestation, mainly divided into hemorrhagic stroke (cerebral ischemia and subarachnoid hemorrhage) and There are two types of ischemic stroke (cerebral infarction and cerebral thrombosis), among which ischemic stroke is the most common. The disease has a sudden onset and a high fatality rate, and is one of the most important fatal diseases in the world. According to statistics, there are 1.2 to 1.5 million new cases of complete cerebral apoplexy in my country every year, 800 to 1 million deaths, about 75% of the survivors are disabled, and the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/18A61P9/10A61P25/00
Inventor 李校堃肖健王晓杰张宏宇王周光虞希冲
Owner WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com